{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:27:28Z","timestamp":1769880448055,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10072-022-06199-1","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T16:03:12Z","timestamp":1655740992000},"page":"5673-5685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The ultimate guide to the anti-CGRP monoclonal antibodies galaxy"],"prefix":"10.1007","volume":"43","author":[{"given":"Davide","family":"Mascarella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-4295","authenticated-orcid":false,"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"6199_CR1","doi-asserted-by":"crossref","unstructured":"Edvinsson L, finestra C a un sito esterno I contenuti a cui indirizza il collegamento verranno aperti in una nuova, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neuro 14(6):338-350","DOI":"10.1038\/s41582-018-0003-1"},{"issue":"19","key":"6199_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Migraine","year":"2020","unstructured":"Migraine AM (2020) N Engl J Med 383(19):1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"issue":"2","key":"6199_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neuroscience.2010.05.016","volume":"169","author":"S Eftekhari","year":"2010","unstructured":"Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L (2010) Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169(2):683\u2013696. https:\/\/doi.org\/10.1016\/j.neuroscience.2010.05.016","journal-title":"Neuroscience"},{"issue":"1","key":"6199_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-015-0575-8","volume":"16","author":"C Lundblad","year":"2015","unstructured":"Lundblad C, Haanes KA, Gr\u00e4nde G, Edvinsson L (2015) Experimental inflammation following dural application of complete Freund\u2019s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain 16(1):91. https:\/\/doi.org\/10.1186\/s10194-015-0575-8","journal-title":"J Headache Pain"},{"issue":"2","key":"6199_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183\u2013187. https:\/\/doi.org\/10.1002\/ana.410280213","journal-title":"Ann Neurol"},{"issue":"10","key":"6199_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30(10):1179\u20131186. https:\/\/doi.org\/10.1177\/0333102410368444","journal-title":"Cephalalgia"},{"issue":"5871","key":"6199_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"SG Amara","year":"1982","unstructured":"Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298(5871):240\u2013244. https:\/\/doi.org\/10.1038\/298240a0","journal-title":"Nature"},{"issue":"9","key":"6199_CR8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1517\/14728222.11.9.1179","volume":"11","author":"L Edvinsson","year":"2007","unstructured":"Edvinsson L (2007) Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets 11(9):1179\u20131188. https:\/\/doi.org\/10.1517\/14728222.11.9.1179","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"6199_CR9","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2020) One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology 95(5):e469\u2013e479. https:\/\/doi.org\/10.1212\/WNL.0000000000010019","journal-title":"Neurology"},{"issue":"6","key":"6199_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"10161","key":"6199_CR11","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 392(10161):2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"The Lancet"},{"issue":"22","key":"6199_CR12","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/WNL.0000000000012029","volume":"96","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M et al (2021) Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology 96(22):e2724\u2013e2735. https:\/\/doi.org\/10.1212\/WNL.0000000000012029","journal-title":"Neurology"},{"issue":"6","key":"6199_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"9","key":"6199_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"issue":"8","key":"6199_CR15","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454. https:\/\/doi.org\/10.1177\/0333102418779543","journal-title":"Cephalalgia"},{"issue":"24","key":"6199_CR16","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221. https:\/\/doi.org\/10.1212\/WNL.0000000000006640","journal-title":"Neurology"},{"issue":"10","key":"6199_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology. 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"The Lancet Neurology."},{"issue":"19","key":"6199_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"issue":"22","key":"6199_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"10203","key":"6199_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet 394(10203):1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"The Lancet"},{"issue":"3","key":"6199_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"6199_CR22","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"10","key":"6199_CR23","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/head.13997","volume":"60","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Cohen JM, Bibeau K et al (2020) Reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from HALO CM study. Headache J Head Face Pain 60(10):2444\u20132453. https:\/\/doi.org\/10.1111\/head.13997","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"6199_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"issue":"20","key":"6199_CR25","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology"},{"issue":"11\u201312","key":"6199_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/03331024211010305","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Burstein R, Buse DC et al (2021) Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia 41(11\u201312):1152\u20131160. https:\/\/doi.org\/10.1177\/03331024211010305","journal-title":"Cephalalgia"},{"issue":"2","key":"6199_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache J Head Face Pain 61(2):363\u2013372. https:\/\/doi.org\/10.1111\/head.14032","journal-title":"Headache J Head Face Pain"},{"issue":"9","key":"6199_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache J Head Face Pain 61(9):1351\u20131363. https:\/\/doi.org\/10.1111\/head.14194","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"6199_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"for the GARLIT Study Group, Vernieri F, Altamura C et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"issue":"12","key":"6199_CR30","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM (2021) Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. Eur J Neurol 28(12):4194\u20134203. https:\/\/doi.org\/10.1111\/ene.15075","journal-title":"Eur J Neurol"},{"issue":"1","key":"6199_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belv\u00eds","year":"2021","unstructured":"Belv\u00eds R, Irimia P, Pozo-Rosich P et al (2021) MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22(1):74. https:\/\/doi.org\/10.1186\/s10194-021-01267-x","journal-title":"J Headache Pain"},{"key":"6199_CR32","doi-asserted-by":"publisher","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334. https:\/\/doi.org\/10.3389\/fneur.2021.805334","journal-title":"Front Neurol"},{"issue":"10","key":"6199_CR33","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789\u20133798. https:\/\/doi.org\/10.1007\/s00415-021-10523-8","journal-title":"J Neurol"},{"issue":"10","key":"6199_CR34","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache J Head Face Pain 60(10):2555\u20132562. https:\/\/doi.org\/10.1111\/head.13968","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"6199_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"2","key":"6199_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43(2):1273\u20131280. https:\/\/doi.org\/10.1007\/s10072-021-05426-5","journal-title":"Neurol Sci"},{"issue":"1","key":"6199_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22(1):120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain"},{"key":"6199_CR38","doi-asserted-by":"publisher","unstructured":"Boudreau GP (2020) Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 4(1). https:\/\/doi.org\/10.33425\/2639-846X.1037","DOI":"10.33425\/2639-846X.1037"},{"issue":"1","key":"6199_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23(1):46. https:\/\/doi.org\/10.1186\/s10194-022-01396-x","journal-title":"J Headache Pain"},{"issue":"3","key":"6199_CR40","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s12325-021-01632-x","volume":"38","author":"DK Kuruppu","year":"2021","unstructured":"Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL (2021) Onset, maintenance, and cessation of effect of galcanezumab for prevention of migraine: a narrative review of three randomized placebo-controlled trials. Adv Ther 38(3):1614\u20131626. https:\/\/doi.org\/10.1007\/s12325-021-01632-x","journal-title":"Adv Ther"},{"issue":"1","key":"6199_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y","journal-title":"J Headache Pain"},{"key":"6199_CR42","doi-asserted-by":"publisher","unstructured":"Guerzoni S, Baraldi C, Pensato U, et al (2022) Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. Published online https:\/\/doi.org\/10.1007\/s10072-022-05870-x","DOI":"10.1007\/s10072-022-05870-x"},{"issue":"4\u20135","key":"6199_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Overeem LH et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42(4\u20135):326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"key":"6199_CR44","doi-asserted-by":"publisher","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti\u2010calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Euro J of Neurology. Published online February 13, 2022:ene.15260. https:\/\/doi.org\/10.1111\/ene.15260","DOI":"10.1111\/ene.15260"},{"key":"6199_CR45","doi-asserted-by":"publisher","unstructured":"Schiano di Cola F, Caratozzolo S, Venturelli E, et al (2021) Erenumab discontinuation following 12-month treatment: a multicentric observational real-life study. Neurol Clin Pract. Published online July 1, 2021:https:\/\/doi.org\/10.1212\/CPJ.0000000000001112","DOI":"10.1212\/CPJ.0000000000001112"},{"issue":"11\u201312","key":"6199_CR46","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment \u2013 a real-life cohort study. Cephalalgia 41(11\u201312):1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"issue":"5","key":"6199_CR47","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"issue":"2","key":"6199_CR48","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43(2):1273\u20131280. https:\/\/doi.org\/10.1007\/s10072-021-05426-5","journal-title":"Neurol Sci"},{"issue":"5","key":"6199_CR49","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/ene.15260","volume":"29","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Euro J Neurol 29(5):1505\u20131513. https:\/\/doi.org\/10.1111\/ene.15260","journal-title":"Euro J Neurol"},{"key":"6199_CR50","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Brunelli N, et al (2021) Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3\u2010month observational, longitudinal, cohort, multicenter, Italian real\u2010life study. Eur J Neurol. Published online December 6, 2021:ene.15197. https:\/\/doi.org\/10.1111\/ene.15197","DOI":"10.1111\/ene.15197"},{"key":"6199_CR51","doi-asserted-by":"publisher","unstructured":"Peng KP, Basedau H, Oppermann T, May A (2022) Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction. Pain. 2022;Publish Ahead of Print. https:\/\/doi.org\/10.1097\/j.pain.0000000000002614","DOI":"10.1097\/j.pain.0000000000002614"},{"key":"6199_CR52","doi-asserted-by":"publisher","unstructured":"Zecca C, Cargnin S, Schankin C, et al (2022) Clinic and genetic predictors in response to erenumab. Euro J of Neurology. Published online January 21, 2022:ene.15236. https:\/\/doi.org\/10.1111\/ene.15236","DOI":"10.1111\/ene.15236"},{"key":"6199_CR53","doi-asserted-by":"publisher","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11(8). https:\/\/doi.org\/10.1002\/brb3.2260","DOI":"10.1002\/brb3.2260"},{"issue":"1","key":"6199_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22(1):1. https:\/\/doi.org\/10.1186\/s10194-020-01213-3","journal-title":"J Headache Pain"},{"issue":"1","key":"6199_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G et al (2021) Psychological predictors of negative treatment outcome with erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22(1):114. https:\/\/doi.org\/10.1186\/s10194-021-01333-4","journal-title":"J Headache Pain"},{"issue":"1","key":"6199_CR56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21(1):76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"issue":"10","key":"6199_CR57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12(10):575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"6199_CR58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84. https:\/\/doi.org\/10.1186\/s10194-020-01151-0","journal-title":"J Headache Pain"},{"key":"6199_CR59","doi-asserted-by":"publisher","unstructured":"Pensato U, Baraldi C, Favoni V, et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia. Published online February 9, 2022:033310242110677. https:\/\/doi.org\/10.1177\/03331024211067791","DOI":"10.1177\/03331024211067791"},{"key":"6199_CR60","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc (2021) A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous\/subcutaneous and subcutaneous) of TEV-48125 versus placebo for the prevention of epidosic cluster headache. clinicaltrials.gov; 2021. Accessed 13 Apr\u00a02022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02945046"},{"key":"6199_CR61","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc (2021) A multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study comparing the efficacy and safety of 2 dose regimens (intravenous\/subcutaneous and subcutaneous) of TEV-48125 versus placebo for the prevention of chronic cluster headache. clinicaltrials.gov; 2021. Accessed 13 Apr\u00a02022. https:\/\/clinicaltrials.gov\/ct2\/show\/nct02964338"},{"issue":"2","key":"6199_CR62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M et al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381(2):132\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1813440","journal-title":"N Engl J Med"},{"issue":"9","key":"6199_CR63","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Goadsby PJ, Lucas C et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40(9):935\u2013948. https:\/\/doi.org\/10.1177\/0333102420905321","journal-title":"Cephalalgia"},{"issue":"14","key":"6199_CR64","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","volume":"40","author":"R Ruscheweyh","year":"2020","unstructured":"Ruscheweyh R, Broessner G, Go\u00dfrau G et al (2020) Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia 40(14):1574\u20131584. https:\/\/doi.org\/10.1177\/0333102420949866","journal-title":"Cephalalgia"},{"key":"6199_CR65","unstructured":"H. Lundbeck (2022) A\/S Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headache. clinicaltrials.gov; 2022. Accessed 11 Apr\u00a02022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04688775"},{"key":"6199_CR66","unstructured":"H. Lundbeck (2022) A\/S. Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache. clinicaltrials.gov; 2022. Accessed 11 Apr\u00a02022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05064397"},{"issue":"1","key":"6199_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s10194-020-01167-6","volume":"21","author":"JM Pavlovic","year":"2020","unstructured":"Pavlovic JM, Paemeleire K, G\u00f6bel H et al (2020) Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain 21(1):95. https:\/\/doi.org\/10.1186\/s10194-020-01167-6","journal-title":"J Headache Pain"},{"issue":"3","key":"6199_CR68","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/brainsci11030370","volume":"11","author":"R Ornello","year":"2021","unstructured":"Ornello R, Frattale I, Caponnetto V, De Matteis E, Pistoia F, Sacco S (2021) Menstrual headache in women with chronic migraine treated with erenumab: an observational case series. Brain Sci 11(3):370. https:\/\/doi.org\/10.3390\/brainsci11030370","journal-title":"Brain Sci"},{"issue":"2","key":"6199_CR69","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40122-021-00273-w","volume":"10","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Orologio I, Bonavita S et al (2021) Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther 10(2):1203\u20131214. https:\/\/doi.org\/10.1007\/s40122-021-00273-w","journal-title":"Pain Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06199-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:13:26Z","timestamp":1660709606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06199-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6199"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06199-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any study with human subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}